Thank you for your support for this blog

Stoxx 50 15min delayed

Menü:. Wirtschaftsdaten - Wirtschaft - Quergelesen Nachrichten aus:

Der aktuelle Nachrichten - Überblick:

Global - 4wards

Wirtschaft - Quergelesen

Europa - Wirtschaft

Deutschland - Wirtschaft

Österreich - Wirtschaft

Schweiz - Wirtschaft

ATX realtime

Shadow Stats

Chart of U.S. Money Supply Growth

Donnerstag, 12. März 2009

Gilead to buy CV Therapeutics for $1.4 billion

Biotechnology company Gilead Sciences Inc. said Thursday it will buy CV Therapeutics for about $1.4 billion as a wave of consolidation in the drug industry continues.

Gilead, best known for its HIV drugs, said it will pay $20 per share in cash for Palo Alto, Calif.-based CV Therapeutics. Last year Astellas Pharma of Japan tried to buy CV for $1 billion, or $16 per share. CV's board has approved the sale and recommends shareholders tender their stock in support.

CV Therapeutics rejected that offer. Its shares closed at $16 Wednesday, which makes Gilead's offer a 25 percent premium.... more details here...

Keine Kommentare:

Kommentar veröffentlichen